ADV 1002401

Drug Profile

ADV 1002401

Alternative Names: ADV-1002401; GKM-001

Latest Information Update: 15 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advinus Therapeutics
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2015 Phase-II clinical trials in Type-2 diabetes mellitus in India (PO)
  • 29 Nov 2011 Advinus Therapeutics completes a phase I trial in Type-2 diabetes mellitus in India
  • 07 Sep 2010 ADV 1002401 is available for licensing in World (www.advinus.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top